MEDICAL BIOTECHNOLOGY AND ALZHEIMER'S DISEASE: NEW HOPES (EDITORIAL)

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

AKHONDZADEH SHAHIN

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Avicenna Journal of Medical Biotechnology Year:2016 | Volume:8 | Issue:2 Page(s): 0-0

Download Full-Text

View:

395

Download:

117

Cites:

Information Journal Paper

Title

MEDICAL BIOTECHNOLOGY AND ALZHEIMER'S DISEASE: NEW HOPES (EDITORIAL)

Author(s)

AKHONDZADEH SHAHIN | Issue Writer Certificate

Keywords

Not Registered.

Abstract

Alzheimer’s Disease (AD), the leading cause of dementia worldwide, is an irreversible progressive neurodegenerative disorder characterized by cognitive impairment and functional disability 1-3. Devastating nature of AD leads to serious social and economic impacts on the healthcare systems which implies the necessity of its proper management 1-3. It has been demonstrated that patients’ quality of life and their overall prognosis has a significant negative correlation with the severity of AD. Patients with severe AD need full-time care and assistance with some basic activities of daily living such as feeding and dressing in addition to severe deterioration in various domains of their cognitive functioning. Progress to a cure for AD has been hampered by the lack of information about the biology of the disease. The therapies currently approved for Alzheimer’s disease work by treating the patients’ symptoms, improving their cognitive and overall functions 4-8. Increasingly, however, experts are intent on slowing or halting the disease process, before it has ravaged patients’ brains. A lot of data is being generated on changes in imaging biomarkers before patients really become clinically significantly impaired. For example, there has been a lot of great work done in identifying patients early based on these biomarkers. The current therapeutic market is valued at $3 to $4 billion, shared among drugs that temporarily delay disease progression or address the symptoms but do not alter the underlying disease. Currently, medical biotechnology has brought new hopes in the treatment of Alzheimer's disease. For example one of the ongoing trials is related to bapineuzumab. Bapineuzumab is a monoclonal antibody (mAb) to target and clear b-amyloid. This vaccine is the first new drug aimed at slowing or even halting AD progression.

Cites

No record.

References

No record.

Cite

APA: Copy

AKHONDZADEH, SHAHIN. (2016). MEDICAL BIOTECHNOLOGY AND ALZHEIMER'S DISEASE: NEW HOPES (EDITORIAL). AVICENNA JOURNAL OF MEDICAL BIOTECHNOLOGY (AJMB), 8(2), 0-0. SID. https://sid.ir/paper/313901/en

Vancouver: Copy

AKHONDZADEH SHAHIN. MEDICAL BIOTECHNOLOGY AND ALZHEIMER'S DISEASE: NEW HOPES (EDITORIAL). AVICENNA JOURNAL OF MEDICAL BIOTECHNOLOGY (AJMB)[Internet]. 2016;8(2):0-0. Available from: https://sid.ir/paper/313901/en

IEEE: Copy

SHAHIN AKHONDZADEH, “MEDICAL BIOTECHNOLOGY AND ALZHEIMER'S DISEASE: NEW HOPES (EDITORIAL),” AVICENNA JOURNAL OF MEDICAL BIOTECHNOLOGY (AJMB), vol. 8, no. 2, pp. 0–0, 2016, [Online]. Available: https://sid.ir/paper/313901/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops